Predictors of infliximab refractory intestinal Behçet’s syndrome: A retrospective cohort study from the Shanghai Behçet’s syndrome database
Modern Rheumatology · 2023
DOI: 10.1093/mr/roab127 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Modern Rheumatology, 2023. Verfasst von Hua-Fang Bao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology and Immunology, Huadong Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Behcet Syndrome, Intestinal Diseases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation.
Abstract (Originalsprache)
Objectives
This retrospective cohort study aimed to find out predictors and early biomarkers of Infliximab (IFX) refractory intestinal Behçet’s syndrome (intestinal BS).
Methods
We collected the baseline clinical characteristics, laboratory parameters, and concomitant therapies of intestinal BS patients treated by IFX from the Shanghai Behçet’s syndrome database. After 1 year IFX therapy, intestinal BS patients with non-mucosal healing (NMH, intestinal ulcers detected by colonoscopy) and/or no clinical remission [NCR, scores of the disease activity index for intestinal Behçet’s disease (DAIBD) ≥20] were defined as IFX refractory intestinal BS. Multivariate logistic regression analysis was performed to evaluate the predictors for NMH and NCR in IFX refractory intestinal BS.
Results
In 85 intestinal BS patients, NMH was identified in 29 (34.12%) patients, and NCR was confirmed in 20 (23.53%) patients. Erythrocyte sedimentation rate (ESR; ≥24 mm/h) and free triiodothyronine (fT3; ≤3.3pmol/L) were the independent risk factors of NMH in IFX refractory intestinal BS. Drinking alcohol and the fT3/free thyroxine ratio (fT3/fT4; ≤0.24) were independent risk factors, and thalidomide was an independent protective factor, for NCR in intestinal BS patients treated by IFX.
Conclusion
This study may be applicable for adjusting the therapeutic strategy and sidestepping unnecessary exposure to IFX in intestinal BS patients. Routine assessments of ESR, fT3, and fT3/fT4 ratio are helpful to identify high-risk individuals of IFX refractory intestinal BS. Thalidomide is suggested to be a concomitant therapy with IFX for intestinal BS patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology and Immunology, Huadong Hospital, Fudan University, Shanghai, China.
- Department of Geriatrics, Key Laboratory of Clinical Geriatric Medicine of Shanghai, Huadong Hospital, Fudan University, Shanghai, China.
Förderung
- National Natural Science Foundation
Zitieren
APA
Bao, H. F., Hou, C. C., Ye, B., Zou, J., Luo, D., Cai, J. F., Shen, Y., & Guan, J. L. (2023). Predictors of infliximab refractory intestinal Behçet’s syndrome: A retrospective cohort study from the Shanghai Behçet’s syndrome database. Modern Rheumatology. https://doi.org/10.1093/mr/roab127
Vancouver
Bao HF, Hou CC, Ye B, Zou J, Luo D, Cai JF, et al. Predictors of infliximab refractory intestinal Behçet’s syndrome: A retrospective cohort study from the Shanghai Behçet’s syndrome database. Modern Rheumatology. 2023. doi:10.1093/mr/roab127
BibTeX
@article{Bao2023,
author = {Bao, Hua-Fang and Hou, Cheng-Cheng and Ye, Bo and Zou, Jun and Luo, Dan and Cai, Jian-Fei and Shen, Yan and Guan, Jian-Long},
title = {Predictors of infliximab refractory intestinal Behçet’s syndrome: A retrospective cohort study from the Shanghai Behçet’s syndrome database},
journal = {Modern Rheumatology},
year = {2023},
doi = {10.1093/mr/roab127}
}
EUVIMED